Ocrevus by Genentech — Product Research | aVenture Research
Ocrevus and Ocrevus Zunovo are prescription medicines for relapsing forms of multiple sclerosis and primary progressive multiple sclerosis in adults. They target and reduce specific B cells in the immune system that can cause inflammation and damage to the brain and spinal cord.
Ocrevus is given as an intravenous infusion twice a year, while Ocrevus Zunovo is a subcutaneous injection given twice a year. More than 450,000 people globally have chosen Ocrevus treatments for multiple sclerosis.
First-in-class gut-preferred once-daily oral small-molecule candidate with a novel TL1A+ pathway inhibitor mechanism in Phase 1 for inflammatory bowel disease.
First-in-class gut-preferred once-daily oral small-molecule candidate with a novel TL1A+ pathway inhibitor mechanism in Phase 1 for inflammatory bowel disease.
